NL301184I2 - rurioctocog alfa pegol - Google Patents
rurioctocog alfa pegolInfo
- Publication number
- NL301184I2 NL301184I2 NL301184C NL301184C NL301184I2 NL 301184 I2 NL301184 I2 NL 301184I2 NL 301184 C NL301184 C NL 301184C NL 301184 C NL301184 C NL 301184C NL 301184 I2 NL301184 I2 NL 301184I2
- Authority
- NL
- Netherlands
- Prior art keywords
- rurioctocog
- alfa pegol
- pegol
- rurioctocog alfa
- alfa
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45057803P | 2003-02-26 | 2003-02-26 | |
PCT/US2004/006034 WO2004075923A2 (en) | 2003-02-26 | 2004-02-26 | Polymer-factor viii moiety conjugates |
Publications (1)
Publication Number | Publication Date |
---|---|
NL301184I2 true NL301184I2 (nl) | 2022-07-21 |
Family
ID=32927670
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NL301184C NL301184I2 (nl) | 2003-02-26 | 2022-07-01 | rurioctocog alfa pegol |
Country Status (20)
Country | Link |
---|---|
US (13) | US7199223B2 (nl) |
EP (4) | EP2572732A1 (nl) |
JP (2) | JP5539607B2 (nl) |
KR (1) | KR101085375B1 (nl) |
CN (2) | CN102139114A (nl) |
AU (2) | AU2004215912B2 (nl) |
BE (1) | BE2022C541I2 (nl) |
BR (1) | BRPI0407882B1 (nl) |
CA (2) | CA2788505C (nl) |
DK (1) | DK1596887T3 (nl) |
ES (1) | ES2911435T3 (nl) |
FR (1) | FR22C1043I2 (nl) |
HU (1) | HUE058897T2 (nl) |
IL (1) | IL170424A (nl) |
LT (1) | LT1596887T (nl) |
MX (1) | MXPA05009169A (nl) |
NL (1) | NL301184I2 (nl) |
PT (1) | PT1596887T (nl) |
SI (1) | SI1596887T1 (nl) |
WO (1) | WO2004075923A2 (nl) |
Families Citing this family (147)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7157277B2 (en) | 2001-11-28 | 2007-01-02 | Neose Technologies, Inc. | Factor VIII remodeling and glycoconjugation of Factor VIII |
US7173003B2 (en) | 2001-10-10 | 2007-02-06 | Neose Technologies, Inc. | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF |
US8008252B2 (en) * | 2001-10-10 | 2011-08-30 | Novo Nordisk A/S | Factor VII: remodeling and glycoconjugation of Factor VII |
US7214660B2 (en) * | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
ES2291613T3 (es) * | 2002-01-16 | 2008-03-01 | Biocompatibles Uk Limited | Conjugados de polimeros. |
MXPA04012496A (es) * | 2002-06-21 | 2005-09-12 | Novo Nordisk Healthcare Ag | Glicoformos del factor vii pegilados. |
GB0301014D0 (en) * | 2003-01-16 | 2003-02-19 | Biocompatibles Ltd | Conjugation reactions |
EP2572732A1 (en) | 2003-02-26 | 2013-03-27 | Nektar Therapeutics | Polymer-factor VIII moiety conjugates |
US20070026485A1 (en) | 2003-04-09 | 2007-02-01 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
US8791070B2 (en) | 2003-04-09 | 2014-07-29 | Novo Nordisk A/S | Glycopegylated factor IX |
NZ541374A (en) * | 2003-05-23 | 2008-09-26 | Nektar Therapeutics Al Corp | PEG derivatives having an amidocarbonate linkage |
US7947261B2 (en) | 2003-05-23 | 2011-05-24 | Nektar Therapeutics | Conjugates formed from polymer derivatives having particular atom arrangements |
US9005625B2 (en) | 2003-07-25 | 2015-04-14 | Novo Nordisk A/S | Antibody toxin conjugates |
US7786213B2 (en) * | 2003-10-15 | 2010-08-31 | The Regents Of The University Of California | Biomacromolecule polymer conjugates |
US20080305992A1 (en) | 2003-11-24 | 2008-12-11 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
US20060040856A1 (en) | 2003-12-03 | 2006-02-23 | Neose Technologies, Inc. | Glycopegylated factor IX |
US6887952B1 (en) * | 2004-02-12 | 2005-05-03 | Biosite, Inc. | N-aryl-carbamic acid ester-derived and valeric acid ester-derived cross-linkers and conjugates, and methods for their synthesis and use |
CN101132812A (zh) * | 2004-03-15 | 2008-02-27 | 阿拉巴马耐科塔医药公司 | Hiv进入抑制剂的聚合物基组合物和结合物 |
US8470315B2 (en) | 2004-04-13 | 2013-06-25 | Quintessence Biosciences, Inc. | Non-natural ribonuclease conjugates as cytotoxic agents |
US20080300173A1 (en) | 2004-07-13 | 2008-12-04 | Defrees Shawn | Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1] |
US20080176790A1 (en) | 2004-10-29 | 2008-07-24 | Defrees Shawn | Remodeling and Glycopegylation of Fibroblast Growth Factor (Fgf) |
AU2016203693B2 (en) * | 2004-11-12 | 2018-08-23 | Bayer Healthcare Llc | Site-directed modification of FVIII |
AU2012203813B2 (en) * | 2004-11-12 | 2013-10-24 | Bayer Healthcare Llc | Site-directed modification of FVIII |
NZ555032A (en) | 2004-11-12 | 2010-02-26 | Bayer Healthcare Llc | Site-directed modification of FVIII |
AU2013203348B2 (en) * | 2004-11-12 | 2016-03-03 | Bayer Healthcare Llc | Site-directed modification of FVIII |
PT1835938E (pt) * | 2004-12-27 | 2013-11-06 | Baxter Int | Conjugados de polímero-factor de von willebrand |
EP1858543B1 (en) | 2005-01-10 | 2013-11-27 | BioGeneriX AG | Glycopegylated granulocyte colony stimulating factor |
US7714114B2 (en) | 2005-02-16 | 2010-05-11 | Nektar Therapeutics | Conjugates of an EPO moiety and a polymer |
WO2006102659A2 (en) * | 2005-03-23 | 2006-09-28 | Nektar Therapeutics Al, Corporation | CONJUGATES OF AN hGH MOIETY AND A POLYMER |
EP1871801A2 (en) * | 2005-04-01 | 2008-01-02 | Novo Nordisk Health Care AG | Blood coagulation fviii analogues |
US9187546B2 (en) * | 2005-04-08 | 2015-11-17 | Novo Nordisk A/S | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants |
US8273339B2 (en) | 2005-04-12 | 2012-09-25 | Nektar Therapeutics | Polymer-based compositions and conjugates of antimicrobial agents |
US20080255026A1 (en) | 2005-05-25 | 2008-10-16 | Glycopegylated Factor 1X | Glycopegylated Factor Ix |
WO2006134173A2 (en) * | 2005-06-17 | 2006-12-21 | Novo Nordisk Health Care Ag | Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine |
CN101257926A (zh) * | 2005-08-04 | 2008-09-03 | 尼克塔治疗亚拉巴马公司 | G-csf部分与聚合物的轭合物 |
US20070105755A1 (en) * | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
US20090048440A1 (en) | 2005-11-03 | 2009-02-19 | Neose Technologies, Inc. | Nucleotide Sugar Purification Using Membranes |
US20070141021A1 (en) * | 2005-12-19 | 2007-06-21 | Perry Rosen | Methylmaleimidyl polymer derivatives |
CA2647143A1 (en) | 2006-03-30 | 2007-10-11 | Palatin Technologies, Inc. | Cyclic natriuretic peptide constructs |
US8580746B2 (en) * | 2006-03-30 | 2013-11-12 | Palatin Technologies, Inc. | Amide linkage cyclic natriuretic peptide constructs |
AU2007233123A1 (en) * | 2006-03-30 | 2007-10-11 | Palatin Technologies, Inc. | Linear natriuretic peptide constructs |
EP2010222A1 (en) | 2006-03-31 | 2009-01-07 | Baxter International Inc. | Pegylated factor viii |
US7985839B2 (en) * | 2006-03-31 | 2011-07-26 | Baxter International Inc. | Factor VIII polymer conjugates |
US7645860B2 (en) * | 2006-03-31 | 2010-01-12 | Baxter Healthcare S.A. | Factor VIII polymer conjugates |
US7982010B2 (en) * | 2006-03-31 | 2011-07-19 | Baxter International Inc. | Factor VIII polymer conjugates |
RU2008145084A (ru) * | 2006-05-24 | 2010-06-27 | Ново Нордиск Хелс Кеа Аг (Ch) | Аналоги фактора ix, имеющие пролонгированное время полужизни in vivo |
JP2009541333A (ja) | 2006-06-23 | 2009-11-26 | クインテセンス バイオサイエンシーズ インコーポレーティッド | 修飾リボヌクレアーゼ |
JP2009543868A (ja) | 2006-07-17 | 2009-12-10 | クインテセンス バイオサイエンシーズ インコーポレーティッド | 癌治療に関する方法および組成物 |
CN101516388B (zh) | 2006-07-21 | 2012-10-31 | 诺和诺德公司 | 通过o-联糖基化序列的肽的糖基化 |
US8969532B2 (en) | 2006-10-03 | 2015-03-03 | Novo Nordisk A/S | Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography |
JP5876208B2 (ja) * | 2006-12-15 | 2016-03-02 | バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated | 延長されたinvivo半減期を有する第VIIa因子−(ポリ)シアル酸結合体 |
BRPI0720619B1 (pt) * | 2006-12-27 | 2022-04-05 | Nektar Therapeutics | Composto de fator ix-poli(etileno glicol) com uma ligação liberável, método para preparar o mesmo e composição |
JP5702066B2 (ja) * | 2006-12-27 | 2015-04-15 | ネクター セラピューティクス | 解離可能な連結を有するフォンウィルブランド因子および第viii因子のポリマー共役体 |
DK2144923T3 (da) | 2007-04-03 | 2013-05-13 | Biogenerix Ag | Behandlingsfremgangsmåder under anvendelse af glycopegyleret g-csf |
ES2551123T3 (es) | 2007-06-12 | 2015-11-16 | Ratiopharm Gmbh | Proceso mejorado para la producción de azúcares de nucleótido |
WO2009045539A2 (en) * | 2007-10-05 | 2009-04-09 | Nektar Therapeutics Al, Corporation | Oligomer-corticosteroid conjugates |
EP2205271B1 (en) | 2007-10-08 | 2014-05-21 | Quintessence Biosciences, Inc. | Compositions and methods for ribonuclease-based therapies |
CA2704234A1 (en) * | 2007-11-09 | 2009-05-14 | Baxter International Inc. | Modified recombinant factor viii and von willebrand factor and methods of use |
DK2245456T3 (da) * | 2007-12-27 | 2013-03-04 | Baxter Int | Fremgangsmåde og sammensætninger til specifik påvisning af fysiologisk acceptable polymermolekyler |
CN101965200B (zh) | 2008-02-27 | 2013-06-19 | 诺沃-诺迪斯克有限公司 | 缀合的因子ⅷ分子 |
TWI395593B (zh) | 2008-03-06 | 2013-05-11 | Halozyme Inc | 可活化的基質降解酵素之活體內暫時性控制 |
KR101647932B1 (ko) | 2008-04-14 | 2016-08-11 | 할로자임, 아이엔씨 | 히알루로난 관련 질환 및 상태 치료용 변형된 히알루로니다제 및 그 용도 |
TWI394580B (zh) | 2008-04-28 | 2013-05-01 | Halozyme Inc | 超快起作用胰島素組成物 |
JP5674650B2 (ja) * | 2008-06-04 | 2015-02-25 | バイエル・ヘルスケア・エルエルシー | フォン・ヴィレブランド病の処置のためのfviii変異タンパク質 |
KR101648734B1 (ko) | 2008-06-24 | 2016-08-18 | 체에스엘 베링 게엠베하 | 연장된 생체내 반감기를 갖는 인자 viii, 폰 빌레브란트 인자 또는 이들의 복합체 |
WO2010014258A2 (en) * | 2008-08-01 | 2010-02-04 | Nektar Therapeutics Al, Corporation | Conjugates having a releasable linkage |
AU2009282747B2 (en) * | 2008-08-22 | 2015-04-02 | Takeda Pharmaceutical Company Limited | Polymeric benzyl carbonate-derivatives |
EP2334695B1 (en) | 2008-10-01 | 2015-12-23 | Quintessence Biosciences, Inc. | Therapeutic ribonucleases |
JP4966434B2 (ja) * | 2008-10-15 | 2012-07-04 | バクスター・インターナショナル・インコーポレイテッド | 結合抗体の存在下における組換え血液凝固因子のpeg化 |
SI2349342T1 (sl) * | 2008-10-17 | 2018-10-30 | Baxalta GmbH | Modificirani krvni faktorji, ki obsegajo nizko stopnjo v vodi topnega polimera |
JP5281358B2 (ja) * | 2008-10-27 | 2013-09-04 | 学校法人常翔学園 | 高分子、経上皮吸収促進剤、及び医薬用製剤 |
US20120027743A1 (en) * | 2008-11-03 | 2012-02-02 | Bayer Healthcare Llc | Method for the Treatment of Hemophilia |
PT3037529T (pt) | 2008-12-09 | 2019-05-31 | Halozyme Inc | Polipéptidos ph20 estendidos solúveis e suas utilizações |
CA2748662A1 (en) * | 2009-01-19 | 2010-07-22 | Bayer Healthcare Llc | Protein conjugate having an endopeptidase-cleavable bioprotective moiety |
CN102348715B (zh) | 2009-02-03 | 2017-12-08 | 阿穆尼克斯运营公司 | 延伸重组多肽和包含该延伸重组多肽的组合物 |
WO2010102886A1 (en) * | 2009-02-19 | 2010-09-16 | Novo Nordisk A/S | Modification of factor viii |
EP2437786B1 (en) | 2009-06-01 | 2016-05-18 | Yeda Research and Development Co. Ltd. | Prodrugs containing albumin binding probe |
US8809501B2 (en) | 2009-07-27 | 2014-08-19 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
US8642737B2 (en) | 2010-07-26 | 2014-02-04 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
EP3081233B1 (en) | 2009-07-27 | 2020-12-23 | Baxalta GmbH | Glycopolysialylation of proteins other than blood coagulation proteins |
DK2459224T3 (en) | 2009-07-27 | 2016-07-25 | Baxalta GmbH | Blodstørkningsproteinkonjugater |
ES2856055T3 (es) | 2009-07-27 | 2021-09-27 | Baxalta GmbH | Glicopolisialilación de proteínas diferentes de las proteínas de coagulación de la sangre |
AU2010290077C1 (en) | 2009-08-24 | 2015-12-03 | Bioverativ Therapeutics Inc. | Coagulation factor IX compositions and methods of making and using same |
DK2477603T3 (en) | 2009-09-17 | 2016-06-13 | Baxalta Inc | STABLE CO-DEVELOPMENT OF hyaluronidase and Immunoglobulin, AND METHODS OF USE THEREOF |
KR101872203B1 (ko) * | 2010-04-20 | 2018-08-02 | 옥타파마 아게 | 약학 단백질을 위한 신규한 안정화제 |
GB201007356D0 (en) | 2010-04-30 | 2010-06-16 | Leverton Licence Holdings Ltd | Conjugated factor VIIa |
GB201007357D0 (en) * | 2010-04-30 | 2010-06-16 | Leverton Licence Holdings Ltd | Conjugated factor VIII |
WO2012006623A1 (en) | 2010-07-09 | 2012-01-12 | Biogen Idec Hemophilia Inc. | Systems for factor viii processing and methods thereof |
ES2661089T3 (es) | 2010-07-20 | 2018-03-27 | Halozyme Inc. | Métodos de tratamiento o prevención de los efectos secundarios adversos asociados con la administración de un agente anti-hialuronano |
TWI595004B (zh) | 2010-11-03 | 2017-08-11 | 介控生化科技公司 | 經修飾之第九因子多胜肽及其用途 |
PL2654794T3 (pl) | 2010-12-22 | 2020-07-27 | Baxalta GmbH | Materiały i sposoby sprzęgania rozpuszczalnej w wodzie pochodnej kwasu tłuszczowego z białkiem |
WO2012109387A1 (en) | 2011-02-08 | 2012-08-16 | Halozyme, Inc. | Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia |
WO2012140647A2 (en) | 2011-04-11 | 2012-10-18 | Yeda Research And Development Co. Ltd | Albumin binding probes and drug conjugates thereof |
WO2012140650A2 (en) | 2011-04-12 | 2012-10-18 | Hepacore Ltd. | Conjugates of carboxy polysaccharides with fibroblast growth factors and variants thereof |
WO2012174480A2 (en) | 2011-06-17 | 2012-12-20 | Halozyme, Inc. | Continuous subcutaneous insulin infusion methods with a hyaluronan degrading enzyme |
MX340172B (es) | 2011-06-17 | 2016-06-28 | Halozyme Inc | Formulaciones estables de una enzima degradadora de hialuronano. |
US20130011378A1 (en) | 2011-06-17 | 2013-01-10 | Tzung-Horng Yang | Stable formulations of a hyaluronan-degrading enzyme |
WO2013040501A1 (en) | 2011-09-16 | 2013-03-21 | Pharmathene, Inc. | Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and uses thereof |
BR112014009797A2 (pt) | 2011-10-24 | 2020-10-27 | Halozyme, Inc. | diagnóstico de companhia para terapia de agente anti-hialuronano e métodos de uso do mesmo |
PT3130347T (pt) | 2011-12-30 | 2019-12-10 | Halozyme Inc | Variantes de polipéptidos de ph20, suas formulações e utilizações |
BR112014017165B1 (pt) * | 2012-01-12 | 2023-05-02 | Bioverativ Therapeutics Inc | Proteína quimérica compreendendo uma proteína de fator viii, composição farmacêutica, e seus usos |
PL2814502T3 (pl) | 2012-02-15 | 2018-02-28 | Csl Behring Gmbh | Warianty czynnika von Willebranda mające ulepszone powinowactwo do wiązania czynnika VIII |
WO2013122617A1 (en) | 2012-02-15 | 2013-08-22 | Amunix Operating Inc. | Factor viii compositions and methods of making and using same |
CA2864126A1 (en) * | 2012-02-15 | 2013-08-22 | Biogen Idec Ma Inc. | Recombinant factor viii proteins |
CA2986512C (en) | 2012-04-04 | 2022-05-17 | Halozyme, Inc. | Combination therapy with an anti-hyaluronan agent and a tumor-targeted taxane |
GB2516388A (en) * | 2012-04-16 | 2015-01-21 | Cantab Biopharmaceuticals Patents Ltd | Optimised subcutaneous therapeutic agents |
JP2015521589A (ja) | 2012-06-08 | 2015-07-30 | バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. | プロコアグラント化合物 |
CA2875247A1 (en) | 2012-06-08 | 2013-12-12 | Biogen Idec Ma Inc. | Chimeric clotting factors |
US20140017265A1 (en) * | 2012-07-05 | 2014-01-16 | Mersana Therapeutics, Inc. | Terminally Modified Polymers and Conjugates Thereof |
EP4269431A1 (en) | 2012-07-11 | 2023-11-01 | Bioverativ Therapeutics Inc. | Factor viii complex with xten and von willebrand factor protein, and uses thereof |
EP2882457A1 (en) * | 2012-08-13 | 2015-06-17 | Novo Nordisk A/S | Liquid factor viii formulations |
US9278124B2 (en) | 2012-10-16 | 2016-03-08 | Halozyme, Inc. | Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods |
WO2014063108A1 (en) | 2012-10-18 | 2014-04-24 | Biogen Idec Ma Inc. | Methods of using a fixed dose of a clotting factor |
RU2677796C9 (ru) | 2013-03-05 | 2019-03-15 | Ханми Фарм. Ко., Лтд. | Улучшенный способ получения конъюгата физиологически активного полипептида с высоким выходом |
WO2014160272A1 (en) * | 2013-03-13 | 2014-10-02 | Emory University | Targeted elimination of factor viii immune cells |
CA2899089C (en) | 2013-03-15 | 2021-10-26 | Biogen Ma Inc. | Factor ix polypeptide formulations |
US20200157159A1 (en) | 2013-04-16 | 2020-05-21 | The Board Of Regents Of The University Of Oklahoma | Peptide compounds and compositions thereof |
EP2796145B1 (en) | 2013-04-22 | 2017-11-01 | CSL Ltd. | A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge |
TW201534726A (zh) | 2013-07-03 | 2015-09-16 | Halozyme Inc | 熱穩定ph20玻尿酸酶變異體及其用途 |
EP3033098B1 (en) | 2013-08-14 | 2022-06-22 | Bioverativ Therapeutics Inc. | Recombinant factor viii proteins |
US10548953B2 (en) | 2013-08-14 | 2020-02-04 | Bioverativ Therapeutics Inc. | Factor VIII-XTEN fusions and uses thereof |
BR112016015512B1 (pt) | 2014-01-10 | 2023-12-19 | Bioverativ Therapeutics Inc | Proteína quimérica, composição farmacêutica e seus usos |
EP3114138B1 (en) | 2014-03-05 | 2021-11-17 | Pfizer Inc. | Improved muteins of clotting factor viii |
DK3164150T3 (da) | 2014-07-02 | 2021-02-08 | CSL Behring Lengnau AG | Modificeret von willebrand-faktor |
WO2016033555A1 (en) | 2014-08-28 | 2016-03-03 | Halozyme, Inc. | Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor |
JP6625627B2 (ja) | 2014-10-14 | 2019-12-25 | ハロザイム インコーポレイテッド | アデノシンデアミナーゼ−2(ada2)、その変異体の組成物およびそれを使用する方法 |
MA40835A (fr) | 2014-10-23 | 2017-08-29 | Biogen Ma Inc | Anticorps anti-gpiib/iiia et leurs utilisations |
MA40861A (fr) | 2014-10-31 | 2017-09-05 | Biogen Ma Inc | Anticorps anti-glycoprotéines iib/iiia |
EP3265483B1 (en) | 2015-03-06 | 2019-12-11 | CSL Behring Lengnau AG | Modified von willebrand factor having improved half-life |
RU2017145014A (ru) | 2015-05-22 | 2019-06-24 | Цсл Беринг Ленгнау Аг | Усеченные полипептиды фактора фон виллебранда для лечения гемофилии |
BR112017024714A2 (pt) | 2015-05-22 | 2018-09-11 | Csl Behring Recombinant Facility Ag | métodos para preparação do fator de von willebrand modificado |
CN108472337B (zh) | 2015-08-03 | 2022-11-25 | 比奥贝拉蒂治疗公司 | 因子ix融合蛋白以及其制备和使用方法 |
CN108472338B (zh) | 2016-01-07 | 2022-12-30 | 康诺贝林伦瑙有限公司 | 突变的截短的von Willebrand因子 |
SG10201912857XA (en) | 2016-01-07 | 2020-02-27 | CSL Behring Lengnau AG | Mutated von willebrand factor |
JP7235511B2 (ja) * | 2016-06-24 | 2023-03-08 | モガム・インスティテュート・フォー・バイオメディカル・リサーチ | 組換え型一本鎖fviiiおよびその化学コンジュゲート |
KR102580477B1 (ko) | 2016-07-22 | 2023-09-19 | 넥타르 테라퓨틱스 | 옥심-함유 결합을 갖는 인자 viii 모이어티의 컨쥬게이트 |
TW201828975A (zh) | 2016-11-11 | 2018-08-16 | 瑞士商Csl貝林重組技能公司 | 用於治療血友病之截短型類血友病因子(von Willebrand factor)多肽類 |
SG11201903954WA (en) | 2016-11-11 | 2019-05-30 | CSL Behring Lengnau AG | Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder |
BR112019011115A2 (pt) | 2016-12-02 | 2019-10-01 | Bioverativ Therapeutics Inc | métodos para tratar artropatia hemofílica usando fatores de coagulação quiméricos |
KR20190091292A (ko) | 2016-12-02 | 2019-08-05 | 바이오버라티브 테라퓨틱스 인크. | 응고 인자에 대한 면역 내성 유도 방법 |
SG11201912071QA (en) | 2017-06-22 | 2020-01-30 | Catalyst Biosciences Inc | Modified membrane type serine protease 1 (mtsp-1) polypeptides and methods of use |
US11491212B1 (en) | 2017-09-27 | 2022-11-08 | Catalyst Biosciences, Inc. | Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B |
US20190351031A1 (en) | 2018-05-16 | 2019-11-21 | Halozyme, Inc. | Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20 |
WO2020018943A1 (en) * | 2018-07-20 | 2020-01-23 | Hercules Llc | Water soluble or dispersible composition |
CA3176021A1 (en) | 2018-12-28 | 2020-07-02 | Catalyst Biosciences, Inc. | Modified urokinase-type plasminogen activator polypeptides and methods of use |
US11613744B2 (en) | 2018-12-28 | 2023-03-28 | Vertex Pharmaceuticals Incorporated | Modified urokinase-type plasminogen activator polypeptides and methods of use |
WO2021154414A2 (en) | 2020-01-29 | 2021-08-05 | Catalyst Biosciences, Inc. | Gene therapy for hemophilia b with a chimeric aav capsid vector encoding modified factor ix polypeptides |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
JPS59172425A (ja) | 1983-03-18 | 1984-09-29 | Nippon Chemiphar Co Ltd | 新規な血液凝固因子誘導体およびその製造法ならびにそれを含有する血液凝固促進剤 |
DE3481109D1 (de) * | 1983-05-09 | 1990-03-01 | Novo Nordisk As | Antihaemophilie-faktor-viii-konzentrat und dessen herstellungsverfahren. |
US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
US4965199A (en) * | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
DK525384D0 (da) * | 1984-11-05 | 1984-11-05 | Nordisk Insulinlab | Praeparat paa basis af faktor viii til behandling af haemofili a inhibitorpatienter samt fremgangsmaade til fremstilling af et saadan praeparat |
US4970300A (en) * | 1985-02-01 | 1990-11-13 | New York University | Modified factor VIII |
EP0218712B1 (en) | 1985-04-12 | 1992-02-26 | Genetics Institute, Inc. | Novel procoagulant proteins |
AT387234B (de) * | 1987-03-05 | 1988-12-27 | Vogelbusch Gmbh | Vorrichtung zur zuechtung von dauerformen insbesondere filamentoeser mikroorganismen |
US4994439A (en) * | 1989-01-19 | 1991-02-19 | California Biotechnology Inc. | Transmembrane formulations for drug administration |
SE465222C5 (sv) * | 1989-12-15 | 1998-02-10 | Pharmacia & Upjohn Ab | Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning |
US5397771A (en) * | 1990-05-10 | 1995-03-14 | Bechgaard International Research And Development A/S | Pharmaceutical preparation |
IT1248723B (it) * | 1990-06-12 | 1995-01-26 | Scalvo S P A | Processo per la purificazione del fattore viii e fattore viii ottenuto con tale processo |
US5766897A (en) * | 1990-06-21 | 1998-06-16 | Incyte Pharmaceuticals, Inc. | Cysteine-pegylated proteins |
JPH06506217A (ja) | 1991-03-18 | 1994-07-14 | エンゾン,インコーポレーテッド | ポリペプチドまたはグリコポリペプチドとポリマーとのヒドラジン含有結合体 |
DE4111393A1 (de) * | 1991-04-09 | 1992-10-15 | Behringwerke Ag | Stabilisierte faktor viii-praeparationen |
US6376463B1 (en) * | 1992-04-07 | 2002-04-23 | Emory University | Modified factor VIII |
US6037452A (en) * | 1992-04-10 | 2000-03-14 | Alpha Therapeutic Corporation | Poly(alkylene oxide)-Factor VIII or Factor IX conjugate |
AU5006993A (en) | 1992-08-21 | 1994-03-15 | Enzon, Inc. | Novel attachment of polyalkylene oxides to bio-effecting substances |
US5298643A (en) * | 1992-12-22 | 1994-03-29 | Enzon, Inc. | Aryl imidate activated polyalkylene oxides |
AU6029594A (en) | 1993-01-15 | 1994-08-15 | Enzon, Inc. | Factor viii - polymeric conjugates |
US5321095A (en) * | 1993-02-02 | 1994-06-14 | Enzon, Inc. | Azlactone activated polyalkylene oxides |
US5621039A (en) * | 1993-06-08 | 1997-04-15 | Hallahan; Terrence W. | Factor IX- polymeric conjugates |
SE504074C2 (sv) * | 1993-07-05 | 1996-11-04 | Pharmacia Ab | Proteinberedning för subkutan, intramuskulär eller intradermal administrering |
US5446090A (en) | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
US5612039A (en) * | 1994-03-14 | 1997-03-18 | Nini E. Policappelli | Dietary supplement |
WO1996041813A2 (en) * | 1994-11-09 | 1996-12-27 | Offord Robin E | Functionalized polymers for site-specific attachment |
US5569596A (en) * | 1995-01-04 | 1996-10-29 | The Board Of Regents Of The University Of Oklahoma | Method for bacterial reduction of chromium (VI) |
US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
SE9503380D0 (sv) * | 1995-09-29 | 1995-09-29 | Pharmacia Ab | Protein derivatives |
US6158888A (en) | 1996-09-05 | 2000-12-12 | University Of Florida | Materials and methods for improved radiography |
US5804420A (en) * | 1997-04-18 | 1998-09-08 | Bayer Corporation | Preparation of recombinant Factor VIII in a protein free medium |
WO1998051341A1 (en) | 1997-05-14 | 1998-11-19 | The University Of Manitoba | ANTIGEN-mPEG CONJUGATES SUPPRESS HUMORAL AND CELL MEDIATED IMMUNE RESPONSES |
WO1999005333A1 (fr) | 1997-07-22 | 1999-02-04 | Nippon Steel Corporation | Acier cemente particulierement capable d'empecher la recristallisation secondaire des particules pendant la cementation, procede de fabrication, et matiere brute formee pour pieces cementees |
US5985263A (en) | 1997-12-19 | 1999-11-16 | Enzon, Inc. | Substantially pure histidine-linked protein polymer conjugates |
US6358703B1 (en) | 1998-12-10 | 2002-03-19 | Bayer Corporation | Expression system for factor VIII |
CN1210400C (zh) | 1999-01-14 | 2005-07-13 | 博尔德生物技术公司 | 制备含游离半胱氨酸残基的蛋白质的方法 |
US6309633B1 (en) | 1999-06-19 | 2001-10-30 | Nobex Corporation | Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same |
WO2001062827A2 (en) | 2000-02-22 | 2001-08-30 | Shearwater Corporation | N-maleimidyl polymer derivatives |
ATE367398T1 (de) | 2000-05-16 | 2007-08-15 | Bolder Biotechnology Inc | Verfahren zur rückfaltung von proteinen mit freien cysteinresten |
KR100396983B1 (ko) | 2000-07-29 | 2003-09-02 | 이강춘 | 고반응성의 가지 달린 고분자 유도체 및 고분자와 단백질또는 펩타이드의 접합체 |
TW593427B (en) * | 2000-12-18 | 2004-06-21 | Nektar Therapeutics Al Corp | Synthesis of high molecular weight non-peptidic polymer derivatives |
AP1763A (en) * | 2001-05-21 | 2007-08-02 | Nektar Therapeutics | Pulmonary administration of chemically modified insulin |
US6546159B1 (en) | 2001-08-22 | 2003-04-08 | Avanex Corporation | Method and apparatus for compensating differential group delay |
ATE359829T1 (de) * | 2001-10-30 | 2007-05-15 | Nektar Therapeutics Al Corp | Wasserlösliche polymerkonjugate von retinoesäure |
WO2004022629A2 (en) | 2002-09-09 | 2004-03-18 | Nektar Therapeutics Al, Corporation | Method for preparing water-soluble polymer derivatives bearing a terminal carboxylic acid |
RS20050202A (en) * | 2002-09-09 | 2007-08-03 | Nektar Therapeuticals Al.Corporation, | Water-soluble polymer alkanals |
EP1578843B1 (en) * | 2002-12-31 | 2008-07-09 | Nektar Therapeutics Al, Corporation | Methods for the formation of hydrogels using thiosulfonate compositions and uses thereof |
US7208145B2 (en) | 2002-12-31 | 2007-04-24 | Nektar Therapeutics Al, Corporation | Polymeric reagents comprising a ketone or a related functional group |
JP4490413B2 (ja) * | 2003-01-06 | 2010-06-23 | ネクター セラピューティクス アラバマ,コーポレイション | チオール選択的水溶性ポリマー誘導体 |
EP2572732A1 (en) | 2003-02-26 | 2013-03-27 | Nektar Therapeutics | Polymer-factor VIII moiety conjugates |
MXPA05010411A (es) | 2003-03-28 | 2006-05-31 | Biopolymed Inc | Material activo biologicamente conjugado con polimeros biocompatibles con el complejo 1:1, metodo de preparacion del mismo y composicion farmaceutica que lo contienen. |
US20070026485A1 (en) | 2003-04-09 | 2007-02-01 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
US7691603B2 (en) | 2003-04-09 | 2010-04-06 | Novo Nordisk A/S | Intracellular formation of peptide conjugates |
NZ541374A (en) | 2003-05-23 | 2008-09-26 | Nektar Therapeutics Al Corp | PEG derivatives having an amidocarbonate linkage |
KR102612902B1 (ko) | 2016-04-22 | 2023-12-18 | 삼성디스플레이 주식회사 | 투명 전도막 및 이를 포함하는 전자 소자 |
-
2004
- 2004-02-26 EP EP12160604A patent/EP2572732A1/en not_active Withdrawn
- 2004-02-26 EP EP12160605A patent/EP2572733A1/en not_active Withdrawn
- 2004-02-26 CN CN2010105418684A patent/CN102139114A/zh active Pending
- 2004-02-26 PT PT47151659T patent/PT1596887T/pt unknown
- 2004-02-26 HU HUE04715165A patent/HUE058897T2/hu unknown
- 2004-02-26 CN CNA2004800084228A patent/CN1767857A/zh active Pending
- 2004-02-26 EP EP11152599.4A patent/EP2338523B1/en not_active Expired - Lifetime
- 2004-02-26 EP EP04715165.9A patent/EP1596887B1/en not_active Expired - Lifetime
- 2004-02-26 AU AU2004215912A patent/AU2004215912B2/en not_active Expired
- 2004-02-26 LT LTEPPCT/US2004/006034T patent/LT1596887T/lt unknown
- 2004-02-26 BR BRPI0407882-9A patent/BRPI0407882B1/pt active IP Right Grant
- 2004-02-26 DK DK04715165.9T patent/DK1596887T3/da active
- 2004-02-26 SI SI200432519T patent/SI1596887T1/sl unknown
- 2004-02-26 US US10/789,956 patent/US7199223B2/en active Active
- 2004-02-26 MX MXPA05009169A patent/MXPA05009169A/es active IP Right Grant
- 2004-02-26 WO PCT/US2004/006034 patent/WO2004075923A2/en active Application Filing
- 2004-02-26 CA CA2788505A patent/CA2788505C/en not_active Expired - Lifetime
- 2004-02-26 ES ES04715165T patent/ES2911435T3/es not_active Expired - Lifetime
- 2004-02-26 CA CA2517369A patent/CA2517369C/en not_active Expired - Lifetime
- 2004-02-26 KR KR1020057015960A patent/KR101085375B1/ko active IP Right Grant
- 2004-02-26 JP JP2006503916A patent/JP5539607B2/ja not_active Expired - Lifetime
-
2005
- 2005-08-22 IL IL170424A patent/IL170424A/en active IP Right Grant
-
2007
- 2007-02-05 US US11/702,302 patent/US7858749B2/en active Active
-
2008
- 2008-06-06 US US12/157,072 patent/US7863421B2/en not_active Expired - Lifetime
-
2009
- 2009-04-03 AU AU2009201308A patent/AU2009201308B2/en not_active Expired
- 2009-12-11 US US12/636,594 patent/US8247536B2/en not_active Expired - Lifetime
- 2009-12-11 US US12/636,635 patent/US8143378B2/en active Active
- 2009-12-11 US US12/636,469 patent/US8133977B2/en not_active Expired - Lifetime
-
2011
- 2011-07-15 JP JP2011156978A patent/JP2012025747A/ja not_active Withdrawn
-
2012
- 2012-03-27 US US13/431,872 patent/US8519102B2/en not_active Expired - Lifetime
- 2012-03-27 US US13/431,844 patent/US8889831B2/en active Active
- 2012-03-27 US US13/431,862 patent/US8618259B2/en not_active Expired - Lifetime
-
2014
- 2014-10-17 US US14/517,679 patent/US20150038422A1/en not_active Abandoned
-
2015
- 2015-12-09 US US14/964,416 patent/US9999657B2/en not_active Expired - Lifetime
-
2018
- 2018-05-17 US US15/982,932 patent/US11141465B2/en not_active Expired - Lifetime
-
2021
- 2021-09-09 US US17/470,811 patent/US20210401948A1/en active Pending
-
2022
- 2022-07-01 NL NL301184C patent/NL301184I2/nl unknown
- 2022-08-11 FR FR22C1043C patent/FR22C1043I2/fr active Active
- 2022-09-05 BE BE2022C541C patent/BE2022C541I2/fr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NL301184I2 (nl) | rurioctocog alfa pegol | |
NL300989I1 (nl) | damoctocog alfa pegol | |
NL300878I2 (nl) | Lonoctocog alfa | |
ATE363383T1 (de) | Schlingenware | |
DE502004001683D1 (de) | Kabelführung | |
AT502792A5 (de) | Düsenanpressvorrichtung | |
DE502004007911D1 (de) | Wischblatt | |
DE112004000620D2 (de) | Struktoguss | |
DE502004000672D1 (de) | Pigmentpreparationen | |
DE502004001524D1 (de) | Hydrolager | |
ATA662003A (de) | Trink-mundstück | |
ATE446959T1 (de) | Chromenonindole | |
DE502004001629D1 (de) | Bremsenprüfstand | |
DE502004003122D1 (de) | Hydrolager | |
DE502004002978D1 (de) | N-biarylamide | |
DE502004000518D1 (de) | Mitgängergabelhubwagen | |
DE502004006563D1 (de) | Brieftaubenkonstatiersystem | |
DE10394329D2 (de) | Mäanderstent | |
DE502004005162D1 (de) | Leistungsregelvorricthung | |
DE10355350A8 (de) | Elektromodul | |
ATE406350T1 (de) | Prolinylarylacetamide | |
DE112004002227D2 (de) | Nietverarbeitungsgerät | |
DE10329218B4 (de) | Hotflue | |
DE502004007251D1 (de) | En 2-arylpropenalen | |
DE502004004175D1 (de) | Verbrennungskraftmaschime |